Pasireotide vs Rusfertide
Overview
Pasireotide is primarily a hormonal peptide, while Rusfertide is used for weight management & metabolic.
This page compares Pasireotide and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Rusfertide | |
|---|---|---|
| Category | Hormonal | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 19-108 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | once weekly, subcutaneous |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Rusfertide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Rusfertide: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Rusfertide?
- Pasireotide is primarily a hormonal peptide, while Rusfertide is used for weight management & metabolic. Pasireotide is FDA-approved for one or more indications, whereas Rusfertide is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Pasireotide and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Rusfertide FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references